Reelin promoter hypermethylation in schizophrenia - PubMed (original) (raw)
Reelin promoter hypermethylation in schizophrenia
Dennis R Grayson et al. Proc Natl Acad Sci U S A. 2005.
Abstract
Reelin mRNA and protein levels are reduced by approximately 50% in various cortical structures of postmortem brain from patients diagnosed with schizophrenia or bipolar illness with psychosis. In addition, the mRNA encoding the methylating enzyme, DNA methyltransferase 1, is up-regulated in the same neurons that coexpress reelin and glutamic acid decarboxylase 67. We have analyzed the extent and pattern of methylation within the CpG island of the reelin promoter in genomic DNA isolated from cortices of schizophrenia patients and nonpsychiatric subjects. Ten (The Stanley Foundation Neuropathology Consortium) and five (Harvard Brain Collection) schizophrenia patients and an equal number of nonpsychiatric subjects were selected from each brain collection. Genomic DNA was isolated, amplified (from base pair -527 to base pair +322) after bisulphite treatment, and sequenced. The results show that within the promoter region there were interesting regional variations. There was increased methylation at positions -134 and 139, which is particularly important for regulation, because this portion of the promoter is functionally competent based on transient transfection assays. This promoter region binds a protein present in neuronal precursor nuclear extracts that express very low levels of reelin mRNA; i.e., an oligonucleotide corresponding to this region and that contains methylated cytosines binds more tightly to extracts from nonexpressing cells than the nonmethylated counterpart. Collectively, the data show that this promoter region has positive and negative properties and that the function of this complex cis element relates to its methylation status.
Figures
Fig. 1.
Methylation profile of the reelin promoter in NPS and SZP from The Stanley Foundation brain collection. (A and B) Methylation percentages determined by sequencing bisulphite modified genomic DNA from occipital cortices of NPS (A) and SZP (B) are plotted against the position in the reelin promoter (for numbering, see ref. 17). Six clones from each of 10 patients from each group (NPS vs. SZP) were included in the analysis, yielding a theoretical maximum number of 60 methylated bases at any one position. (C) A linear representation of the reelin promoter (17) aligned with the methylation positions shown in A and B.
Fig. 2.
Methylation profile of the reelin promoter in NPS and SZP from the Harvard Brain Collection. (A and B) Methylation percentages determined by sequencing bisulphite modified genomic DNA from prefrontal cortices of NPS (A) and SZP (B) are plotted against the position in the reelin promoter. Eight clones from each of five patients from each group (NPS vs. SZP) were included in the analysis, yielding a theoretical maximum number of 40 (100%) methylated bases at any one position. (C) A linear representation of the reelin promoter (17) aligned with the methylation positions shown in A and B.
Fig. 3.
Methylation profile summary of The Stanley Foundation (A) and Harvard Brain Collection (B). Positions in which the total number of methylated bases exceeded 12 (or 25%) at any given position are included, with SZP (black bars) alongside NPS (white bars).
Fig. 4.
Transfection of the reelin promoter -514 and deletion/luciferase reporter constructs (-198, -155, -127, -115, and -90) into NT2 cells. (Top) The amount of promoter activity is expressed as a function of 5′ flanking sequence present relative to the simian virus 40 promoter transfected in parallel. Data represent the mean obtained from three measurements made from a minimum of three separate experiments after correcting for transfection efficiency. (Middle) The line below the bar graph indicates the amount of 5′ flanking sequence present in the construct (arrows). (Bottom) A linear representation of the reelin promoter deletions aligned with the promoter.
Fig. 5.
Dissociation rate analysis by electromobility shift competition assays. Labeled oligonucleotides were incubated on ice for 30 min with nuclear extracts prepared from NT2 cells. After a 30-min incubation, a 300-fold excess of unlabeled oligonucleotide was added, and aliquots were analyzed by gel mobility shift assay after the indicated times (0–20 min). (A) NT2 cell nuclear extract incubated with labeled WT (nonmethylated oligonucleotide competed by unlabeled methylated oligonucleotide. (B) NT2 cell nuclear extract incubated with labeled methylated oligonucleotide and competed by unlabeled WT oligonucleotide. (C) Specificity of WT and methyl shifts. (Left) WT oligo. Lanes: 1, control shift (no extract); 2, NT2 cell extract; 3, homologous competition (200-fold); 4, Sp1 oligo (nonspecific) competition (200-fold). (Right) Methyl oligo. Lanes: 5, control shift (no extract); 6, NT2 cell extract; 7, homologous competition (200-fold); 8, Sp1 (nonspecific) oligo competition. (D) The dissociation rate was calculated by scanning the shifted bands with a densitometer and fitting the data to an exponential regression (y = span·e-kx), where x is time, y is specific binding, and span is the binding at time 0 and _k_D is the dissociation rate constant (26). ▪, Methyl probe with nonlabeled WT oligo competition; ▪, WT probe with nonlabeled methyl oligo competition. The affinity for the methylated oligo (_k_D = 0.054) was ≈1.7-fold higher than that obtained for the nonmethylated oligo (_k_D = 0.094).
Similar articles
- The human reelin gene: transcription factors (+), repressors (-) and the methylation switch (+/-) in schizophrenia.
Grayson DR, Chen Y, Costa E, Dong E, Guidotti A, Kundakovic M, Sharma RP. Grayson DR, et al. Pharmacol Ther. 2006 Jul;111(1):272-86. doi: 10.1016/j.pharmthera.2005.01.007. Epub 2006 Mar 30. Pharmacol Ther. 2006. PMID: 16574235 Review. - Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report.
Abdolmaleky HM, Cheng KH, Russo A, Smith CL, Faraone SV, Wilcox M, Shafa R, Glatt SJ, Nguyen G, Ponte JF, Thiagalingam S, Tsuang MT. Abdolmaleky HM, et al. Am J Med Genet B Neuropsychiatr Genet. 2005 Apr 5;134B(1):60-6. doi: 10.1002/ajmg.b.30140. Am J Med Genet B Neuropsychiatr Genet. 2005. PMID: 15717292 - On the epigenetic regulation of the human reelin promoter.
Chen Y, Sharma RP, Costa RH, Costa E, Grayson DR. Chen Y, et al. Nucleic Acids Res. 2002 Jul 1;30(13):2930-9. doi: 10.1093/nar/gkf401. Nucleic Acids Res. 2002. PMID: 12087179 Free PMC article. - Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia.
Dong E, Agis-Balboa RC, Simonini MV, Grayson DR, Costa E, Guidotti A. Dong E, et al. Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12578-83. doi: 10.1073/pnas.0505394102. Epub 2005 Aug 19. Proc Natl Acad Sci U S A. 2005. PMID: 16113080 Free PMC article. - The involvement of Reelin in neurodevelopmental disorders.
Folsom TD, Fatemi SH. Folsom TD, et al. Neuropharmacology. 2013 May;68:122-35. doi: 10.1016/j.neuropharm.2012.08.015. Epub 2012 Sep 7. Neuropharmacology. 2013. PMID: 22981949 Free PMC article. Review.
Cited by
- Beyond Glycolysis: Aldolase A Is a Novel Effector in Reelin-Mediated Dendritic Development.
Lagani GD, Sha M, Lin W, Natarajan S, Kankkunen M, Kistler SA, Lampl N, Waxman H, Harper ER, Emili A, Beffert U, Ho A. Lagani GD, et al. J Neurosci. 2024 Oct 16;44(42):e0072242024. doi: 10.1523/JNEUROSCI.0072-24.2024. J Neurosci. 2024. PMID: 39227156 - Epigenetic Regulation in Schizophrenia: Focus on Methylation and Histone Modifications in Human Studies.
Delphin N, Aust C, Griffiths L, Fernandez F. Delphin N, et al. Genes (Basel). 2024 Feb 21;15(3):272. doi: 10.3390/genes15030272. Genes (Basel). 2024. PMID: 38540331 Free PMC article. Review. - DNMT1 downregulation as well as its overexpression distinctly affect mostly overlapping genes implicated in schizophrenia, autism spectrum, epilepsy, and bipolar disorders.
Singh M, Saxena S, Mohan KN. Singh M, et al. Front Mol Neurosci. 2023 Dec 6;16:1275697. doi: 10.3389/fnmol.2023.1275697. eCollection 2023. Front Mol Neurosci. 2023. PMID: 38125006 Free PMC article. - Schizophrenia in the genetic era: a review from development history, clinical features and genomic research approaches to insights of susceptibility genes.
Lv Y, Wen L, Hu WJ, Deng C, Ren HW, Bao YN, Su BW, Gao P, Man ZY, Luo YY, Li CJ, Xiang ZX, Wang B, Luan ZL. Lv Y, et al. Metab Brain Dis. 2024 Jan;39(1):147-171. doi: 10.1007/s11011-023-01271-x. Epub 2023 Aug 5. Metab Brain Dis. 2024. PMID: 37542622 Review.
References
- Petronis, A. (2001) Trends Genet. 17, 142-146. - PubMed
- Petronis, A, Gottesman, I. I., Kan, P., Kennedy, J. L., Basile, V. S., Paterson, A. D. & Popendikyte, V. (2003) Schizophr. Bull. 29, 169-178. - PubMed
- Guidotti, A., Auta, J., Davis, J. M., DiGiorgi-Gerenini, V., Dwivedi, J., Grayson, D. R., Impagnatiello, F., Pandey, G. N., Pesold, C., Sharma, R. F., et al. (2000) Arch. Gen. Psychiatry 57, 1061-1069. - PubMed
- Costa, E., Grayson, D. R., Mitchell, C. P., Tremolizzo, L., Veldic, M. & Guidotti, A. (2004) Crit. Rev. Neurobiol. 15, 121-142. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MH062188/MH/NIMH NIH HHS/United States
- R01 MH062090/MH/NIMH NIH HHS/United States
- R01 MH062682/MH/NIMH NIH HHS/United States
- MH062090/MH/NIMH NIH HHS/United States
- MH62682/MH/NIMH NIH HHS/United States
- R01 MH062188/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical